{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:14:44Z","timestamp":1758672884806,"version":"3.44.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.aed.2025.06.009","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T20:43:32Z","timestamp":1751661812000},"page":"146-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Increased Weight Loss With the Combination of Levoketoconazole and Semaglutide in a Patient With Mild Hypercortisolism"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-1290","authenticated-orcid":false,"given":"Smita","family":"Kargutkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.aed.2025.06.009_bib1","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamasurg.2020.3280","article-title":"Evaluation and treatment of patients with hypercortisolism: a review","volume":"155","author":"Miller","year":"2020","journal-title":"JAMA Surg"},{"issue":"21","key":"10.1016\/j.aed.2025.06.009_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111521","article-title":"Management and medical therapy of mild hypercortisolism","volume":"22","author":"Favero","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.aed.2025.06.009_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/ijms23020673","article-title":"Pathophysiology of mild hypercortisolism: from the bench to the bedside","volume":"23","author":"Favero","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.aed.2025.06.009_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ando.2023.01.005","article-title":"Possible, probable, and certain hypercortisolism: a continuum in the risk of comorbidity","volume":"84","author":"Araujo-Castro","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"10.1016\/j.aed.2025.06.009_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"10.1016\/j.aed.2025.06.009_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.aed.2025.06.009_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Fr\u00edas","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.aed.2025.06.009_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.aed.2025.06.009_bib11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11102-022-01263-7","article-title":"Levoketoconazole in the treatment of patients with endogenous Cushing\u2019s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)","volume":"25","author":"Pivonello","year":"2022","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.aed.2025.06.009_bib12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.aed.2025.06.009_bib13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.aed.2025.06.009_bib14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.aed.2025.06.009_bib15","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3390\/diagnostics12092045","article-title":"Differentiating polycystic ovary syndrome from adrenal disorders","volume":"12","author":"Yesiladali","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"11","key":"10.1016\/j.aed.2025.06.009_bib16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1055\/s-0028-1087186","article-title":"Testosterone and bioavailable testosterone help to distinguish between mild Cushing\u2019s syndrome and polycystic ovarian syndrome","volume":"40","author":"Pall","year":"2008","journal-title":"Horm Metab Res"},{"issue":"4","key":"10.1016\/j.aed.2025.06.009_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/17446651.2021.1945440","article-title":"Levoketoconazole: a novel treatment for endogenous Cushing\u2019s syndrome","volume":"16","author":"Fleseriu","year":"2021","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.aed.2025.06.009_bib18","doi-asserted-by":"crossref","first-page":"e1618","DOI":"10.1210\/clinem\/dgaa989","article-title":"Levoketoconazole, the 2S,4R enantiomer of ketoconazole, a new steroidogenesis inhibitor for Cushing\u2019s syndrome treatment","volume":"106","author":"Creemers","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1 suppl 1","key":"10.1016\/j.aed.2025.06.009_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jcpt.13230","article-title":"A review of GLP-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once-weekly agents","volume":"45","author":"Cornell","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.aed.2025.06.009_bib20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/DMSO.S387116","article-title":"The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials","volume":"16","author":"Aldawsari","year":"2023","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725000566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725000566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T11:27:10Z","timestamp":1758626830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915725000566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S3050915725000566"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2025.06.009","relation":{},"ISSN":["3050-9157"],"issn-type":[{"type":"print","value":"3050-9157"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased Weight Loss With the Combination of Levoketoconazole and Semaglutide in a Patient With Mild Hypercortisolism","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2025.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Association of Clinical Endocrinologists. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}